<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">crystals</journal-id>
      <journal-title>Crystals</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Crystals</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Crystals</abbrev-journal-title>
      <issn pub-type="epub">2073-4352</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/cryst2031201</article-id>
      <article-id pub-id-type="publisher-id">crystals-02-01201</article-id>
      <article-categories>
        <subj-group>
          <subject>Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Synthesis and Crystal Structure of Benzyl [(1<italic>S</italic>)-1-(5-amino-1,3,4-oxadiazol-2-yl)-2-phenylethyl]carbamate</article-title>
      </title-group>
     
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Löser</surname>
            <given-names>Reik</given-names>
          </name>
          <xref rid="af1-crystals-02-01201" ref-type="aff">1</xref>
          <xref rid="fn1-crystals-02-01201" ref-type="fn">†</xref>
          <xref rid="c1-crystals-02-01201" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nieger</surname>
            <given-names>Martin</given-names>
          </name>
          <xref rid="af2-crystals-02-01201" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gütschow</surname>
            <given-names>Michael</given-names>
          </name>
          <xref rid="af1-crystals-02-01201" ref-type="aff">1</xref>
        </contrib>
      </contrib-group>
       <aff id="af1-crystals-02-01201"><label>1 </label>Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, An der Immenburg 4, Bonn 53121, Germany; Email: <email>guetschow@uni-bonn.de</email></aff>
      <aff id="af2-crystals-02-01201"><label>2 </label>Laboratory of Inorganic Chemistry, Department of Chemistry, P.O. Box 55, University of Helsinki, Helsinki FIN-00014, Finland; Email: <email>martin.nieger@helsinki.fi</email></aff>
      <author-notes>
        <fn id="fn1-crystals-02-01201">
          <label>† </label>
          <p>Present address: Institut für Radiopharmazie, Helmholtz-Zentrum Dresden-Rossendorf, Bautzner Landstrasse 400, Dresden 01328, Germany</p>
        </fn>
        <corresp id="c1-crystals-02-01201"><label>*</label> Author  to whom correspondence should be addressed; Email: <email>r.loeser@hzdr.de</email>; Tel.: +49-351-260-3658; Fax: +49-351-260-2915.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>20</day>
        <month>08</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="collection"><month>09</month>
        <year>2012</year>
      </pub-date>
      <volume>2</volume>
      <issue>3</issue>
      <fpage>1201</fpage>
      <lpage>1209</lpage>
      <history>
        <date date-type="received">
          <day>06</day>
          <month>06</month>
          <year>2012</year>
        </date>
        <date date-type="rev-recd">
          <day>20</day>
          <month>07</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>07</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>©  2012 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
          <p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>The conversion of Z-phenylalanine hydrazide with cyanogen bromide resulted in the formation of the corresponding 2-amino-1,3,4-oxadiazole by spontaneous cyclization of the intermediary cyanohydrazide. The molecular structure of the product was confirmed by single crystal X-ray diffraction. Crystals of the title compound where obtained from a saturated solution in a mixture of petroleum ether and ethyl acetate and belong to the monoclinic space group <italic>P</italic>2<sub>1</sub> with unit cell parameters <italic>a</italic> = 9.8152(2) Å, <italic>b</italic> = 9.6305(2) Å, <italic>c</italic> = 9.8465(2) Å, <italic>β</italic> = 116.785(1)°. The asymmetric unit contains one molecule.</p>
      </abstract>
      <kwd-group>
        <kwd>1,3,4-oxadiazoles</kwd>
        <kwd>cyanohydrazides</kwd>
        <kwd>hydrogen bonds</kwd>
        <kwd>edge-to-face interactions</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>1. Introduction</title>
      <p>The replacement of the α-carbon in peptides by a nitrogen atom leads to azapeptides imparting distinct conformational properties to the corresponding peptide chain [<xref ref-type="bibr" rid="B1-crystals-02-01201">1</xref>]. This concept was recently applied to the C-terminal portion of dipeptide nitriles, an important chemotype of cysteine protease inhibitors [<xref ref-type="bibr" rid="B2-crystals-02-01201">2</xref>], affording compounds that revealed higher inhibitory potency than their carbon-based counterparts [<xref ref-type="bibr" rid="B3-crystals-02-01201">3</xref>]. These amino acid-derived cyanohydrazides, also referred to as azadipeptide nitriles, attracted interest in medicinal chemistry-related research [<xref ref-type="bibr" rid="B4-crystals-02-01201">4</xref>]. Notably, peptide derivatives incorporating internal azaglycine residues, the most simple aza-amino acid, are stable in their open-chain form. In contrast to this, the nitrogen analogues of dipeptides nitriles, as represented by cyanohydrazides derived from amino acids, are only existent if both nitrogen atoms are at least methylated [<xref ref-type="bibr" rid="B3-crystals-02-01201">3</xref>]. <italic>N</italic>’-Cyano-<italic>N</italic>,<italic>N</italic>’-dimethylhydrazides can be obtained by reaction of the corresponding <italic>N</italic>,<italic>N</italic>’-dimethylhydrazides with cyanogen bromide. Contrary to that, conversion of unsubstituted hydrazides leads to 2-amino-1,3,4-oxadiazoles by spontaneous cyclization of the intermediary cyanohydrazides [<xref ref-type="bibr" rid="B5-crystals-02-01201">5</xref>,<xref ref-type="bibr" rid="B6-crystals-02-01201">6</xref>], even though open-chain <italic>N</italic>,<italic>N</italic>’-unsubstituted cyanohydrazides have been reported erroneously in the earlier literature [<xref ref-type="bibr" rid="B7-crystals-02-01201">7</xref>].</p>
      <p>The heteroaromatic 1,3,4-oxadiazole ring system for itself is considerably important in the field of biologically active molecules [<xref ref-type="bibr" rid="B8-crystals-02-01201">8</xref>,<xref ref-type="bibr" rid="B9-crystals-02-01201">9</xref>]. In addition, these heterocycles have attracted interest for materials chemistry as well, for example as benchmark electron-transport molecules in light-emitting devices [<xref ref-type="bibr" rid="B10-crystals-02-01201">10</xref>]. The importance of 1,3,4-oxadiazoles is mainly due to their unique geometrical and electronic properties such as high dipole moment and their susceptibility to hydrogen bond contacts. Compared to their 1,2,4-isomers, 1,3,4-oxadiazoles are characterized by a considerably higher dipole moment (1.8 D <italic>versus</italic> 3.1 D, respectively, for the unsubstituted heterocycles) and thus exhibit improved water solubility [<xref ref-type="bibr" rid="B9-crystals-02-01201">9</xref>].</p>
      <p>Due to its rather facile synthetic accessibility, the 1,3,4-oxadiazole system is employed in the design of constrained peptidomimetics [<xref ref-type="bibr" rid="B11-crystals-02-01201">11</xref>,<xref ref-type="bibr" rid="B12-crystals-02-01201">12</xref>].</p>
      <p>Amino acid-derived 2-amino-1,3,4-oxadiazoles have been reported occasionally in the patent literature in the context of IκB kinase inhibitors [<xref ref-type="bibr" rid="B13-crystals-02-01201">13</xref>] and ligands of the cannabinoid receptor CB<sub>1</sub> [<xref ref-type="bibr" rid="B14-crystals-02-01201">14</xref>]. Furthermore, the synthesis of derivatives containing an additional amino acid-derived substituent attached to the exocyclic amino group has been reported [<xref ref-type="bibr" rid="B15-crystals-02-01201">15</xref>].</p>
      <p>In the course of our systematic investigations to synthetically access azadipeptide nitriles [<xref ref-type="bibr" rid="B3-crystals-02-01201">3</xref>] we also converted an <italic>N</italic>,<italic>N</italic>’-unsubstituted hydrazide derived from phenylalanine with cyanogen bromide. Herein, the obtained product and its crystal structure will be described.</p>
    </sec>
    <sec sec-type="results">
      <title>2. Results and Discussion</title>
      <p>The synthesis followed the scheme outlined in <xref ref-type="fig" rid="crystals-02-01201-f001">Figure 1</xref>. Z-protected phenylalanine hydrazide (<bold>1</bold>), which was prepared as published [<xref ref-type="bibr" rid="B3-crystals-02-01201">3</xref>], was reacted with cyanogen bromide using sodium acetate and methanol as solvent. The obtained crude product was purified by recrystallization from a mixture of petroleum ether and ethyl acetate to obtain crystals proved to be suitable for structure analysis.</p>
      <fig id="crystals-02-01201-f001" position="anchor">
        <label>Figure 1</label>
        <caption>
          <p>Synthesis of 2-amino-1,3,4-oxadiazole <bold>2</bold>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="crystals-02-01201-g001.tif"/>
      </fig>
      <p>Data characterizing the crystals as well as parameters for data collection and structure refinement can be found in <xref ref-type="table" rid="crystals-02-01201-t001">Table 1</xref>. The asymmetric unit consists of one molecule whose structure is shown in <xref ref-type="fig" rid="crystals-02-01201-f002">Figure 2</xref>.</p>
      <table-wrap id="crystals-02-01201-t001" position="anchor">
        <object-id pub-id-type="pii">crystals-02-01201-t001_Table 1</object-id>
        <label>Table 1</label>
        <caption>
          <p>Crystal data and parameters for structure refinement of <bold>2</bold>.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="left" valign="middle">Parameter</th>
              <th align="left" valign="middle">Value</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" valign="middle">Empirical formula</td>
              <td align="left" valign="middle">C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub></td>
            </tr>
            <tr>
              <td align="left" valign="middle">Formula weight</td>
              <td align="left" valign="middle">338.36</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Wavelength</td>
              <td align="left" valign="middle">0.71073 Å</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Crystal system, space group</td>
              <td align="left" valign="middle">Monoclinic, <italic>P</italic>2<sub>1</sub> (No. 4)</td>
            </tr>
            <tr>
              <td rowspan="3" align="left" valign="middle">Unit cell dimensions</td>
              <td align="left" valign="middle"><italic>a</italic> = 9.8152(2) Å</td>
            </tr>
            <tr>
            <td align="left" valign="middle"><italic>b</italic> = 9.6305(2) Å <italic>β</italic> = 116.785(1)</td>
            </tr>
            <tr>
            <td align="left" valign="middle"><italic>c</italic> = 9.8465(2) Å</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Volume</td>
              <td align="left" valign="middle">830.88(3) Å<sup>3</sup></td>
            </tr>
            <tr>
              <td align="left" valign="middle">
                <italic>Z</italic>
              </td>
              <td align="left" valign="middle">2</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Density (calcd.)</td>
              <td align="left" valign="middle">1.352 g/cm<sup>3</sup></td>
            </tr>
            <tr>
              <td align="left" valign="middle">Absorption coefficient</td>
              <td align="left" valign="middle">0.095 mm<sup>−</sup><sup>1</sup></td>
            </tr>
            <tr>
              <td align="left" valign="middle"><italic>F</italic>(000)</td>
              <td align="left" valign="middle">356</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Crystal size</td>
              <td align="left" valign="middle">0.30 × 0.20 × 0.10 mm<sup>3</sup></td>
            </tr>
            <tr>
              <td align="left" valign="middle"><italic>θ<sub>max.</sub></italic> for data collection</td>
              <td align="left" valign="middle">27.5°</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Limiting indices</td>
              <td align="left" valign="middle">−12 ≤ <italic>h</italic> ≤ 12, −12 ≤ <italic>k</italic> ≤ 12, −12 ≤ <italic>l</italic> ≤ 12</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Reflections collected/unique</td>
              <td align="left" valign="middle">15066/3795 [<italic>R</italic>(int) = 0.034]</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Completeness to <italic>θ</italic> = 25.00</td>
              <td align="left" valign="middle">99.6%</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Absorption correction</td>
              <td align="left" valign="middle">None</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Refinement method</td>
              <td align="left" valign="middle">Full-matrix least-squares on <italic>F</italic><sup>2</sup></td>
            </tr>
            <tr>
              <td align="left" valign="middle">Data/restraints/parameters</td>
              <td align="left" valign="middle">3795/4/235</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Goodness-of-fit on <italic>F</italic><sup>2</sup></td>
              <td align="left" valign="middle">0.985</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Final <italic>R</italic> indices [<italic>I</italic> &gt; 2<italic>σ</italic>(<italic>I</italic>)]</td>
              <td align="left" valign="middle"><italic>R</italic><sub>1</sub> = 0.029, <italic>wR</italic><sub>2</sub> = 0.061</td>
            </tr>
            <tr>
              <td align="left" valign="middle"><italic>R</italic> indices (all data)</td>
              <td align="left" valign="middle"><italic>R</italic><sub>1</sub> = 0.034, <italic>wR</italic><sub>2</sub> = 0.062</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Absolute structure parameter</td>
              <td align="left" valign="middle">x = −0.1(6) (Flack’s x-parameter [16]); y = 0.0(5) (Hooft’s y-parameter [17])</td>
            </tr>
            <tr>
              <td align="left" valign="middle">Largest diff. peak and hole</td>
              <td align="left" valign="middle">0.116 and −0.193 e A<sup>−</sup><sup>3</sup></td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <fig id="crystals-02-01201-f002" position="anchor">
        <label>Figure 2</label>
        <caption>
          <p>Molecular structure of <bold>2</bold> as represented by the asymmetric unit. Atoms are represented by thermal ellipsoids at the 50% probability level.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="crystals-02-01201-g002.tif"/>
      </fig>
      <p>The compound crystallized in the space group <italic>P</italic>2<sub>1</sub>, which is one of the 65 Sohncke space groups characterized by containing only rotation or screw axes as symmetry elements. This fact combined with the observed optical rotation of the compound in solution indicates that only one enantiomer is present in the crystal structure [<xref ref-type="bibr" rid="B18-crystals-02-01201">18</xref>,<xref ref-type="bibr" rid="B19-crystals-02-01201">19</xref>]. The absolute configuration could not be determined by anomalous dispersion effects in the diffraction measurement on the crystal due to the absence of atoms heavier than oxygen. However, as the complete inversion of the configuration at the phenylalanine-derived C<sub>α</sub> atom is highly unlikely, it can be concluded that the configuration at atom C9 is <italic>S</italic>. This indicates that all synthetic transformations leading to compound <bold>2</bold> starting from enantiopure Z-protected <sc>L</sc>-phenylalanine proceed without racemization at the C<sub>α</sub> atom. The 1,3,4-oxadiazole ring is completely planar, which is in accordance with the aromatic character of this heterocycle. The bond angles for the five-membered ring and the corresponding bond lengths are shown in <xref ref-type="table" rid="crystals-02-01201-t002">Table 2</xref>. The length of the C18-N4 bond is with 1.345 Å similar to the nitrogen-carbon distance observed in other arylamines [<xref ref-type="bibr" rid="B20-crystals-02-01201">20</xref>] and indicates the overlap of the nitrogens lone electron pair with the electron-deficient hetarene.</p>
      <table-wrap id="crystals-02-01201-t002" position="anchor">
        <object-id pub-id-type="pii">crystals-02-01201-t002_Table 2</object-id>
        <label>Table 2</label>
        <caption>
          <p>Bond angles and lengths for the 2-amino-1,3,4-oxadiazole moiety of <bold>2</bold>.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle">Internal angle</th>
              <th align="center" valign="middle">Value (°)</th>
              <th align="center" valign="middle">Bond</th>
              <th align="center" valign="middle">Interatomic distance (Å)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">C17-N2-N3</td>
              <td align="center" valign="middle">106.4(1)</td>
              <td align="center" valign="middle">C17-N2</td>
              <td align="center" valign="middle">1.282(1)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">N2-N3-C18</td>
              <td align="center" valign="middle">105.5(1)</td>
              <td align="center" valign="middle">N2-N3</td>
              <td align="center" valign="middle">1.424(1)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">N3-C18-O3</td>
              <td align="center" valign="middle">113.2(1)</td>
              <td align="center" valign="middle">N3-C18</td>
              <td align="center" valign="middle">1.294(2)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">C18-O3-C17</td>
              <td align="center" valign="middle">102.3(1)</td>
              <td align="center" valign="middle">C18-O3</td>
              <td align="center" valign="middle">1.360(1)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">O3-C17-N2</td>
              <td align="center" valign="middle">112.6(1)</td>
              <td align="center" valign="middle">O3-C17</td>
              <td align="center" valign="middle">1.376(1)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">–</td>
              <td align="center" valign="middle">–</td>
              <td align="center" valign="middle">C18-N4</td>
              <td align="center" valign="middle">1.345(2)</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Three types of intermolecular hydrogen bond contacts could be identified in the crystal structure (<xref ref-type="fig" rid="crystals-02-01201-f003">Figure 3</xref>). Two of them involve the exocyclic amino group (N4) as two-fold hydrogen bond donor forming contacts to the carbonyl oxygen (O1) of one neighboring molecule and one of the ring nitrogen atoms (N2). A further hydrogen bond contact is formed between the other ring nitrogen atom (N3) that is acting as acceptor towards the NH bond (N1) of the carbamate moiety. The atomic distances and geometries of the three hydrogen bonds are listed in <xref ref-type="table" rid="crystals-02-01201-t003">Table 3</xref>. The observation that both ring nitrogens are acting as hydrogen bond acceptors whereas the ring oxygen does not is in agreement with quantum chemical calculations that assign a strong acceptor capacity to the nitrogen atoms of 1,3,4-oxadiazoles [<xref ref-type="bibr" rid="B9-crystals-02-01201">9</xref>].</p>
      
      <p>A hydrogen bond pattern similar to the one observed in the crystal structure of compound <bold>2</bold> has been suggested for the complex of 5-(4-nitrophenyl)-<italic>N</italic>-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine and glycogen synthase kinase 3β (GSK-3β) on the basis of molecular docking studies [<xref ref-type="bibr" rid="B21-crystals-02-01201">21</xref>]. The results of this <italic>in silico</italic> study provided evidence for the formation of hydrogen bond contacts between the 1,3,4-oxadiazol-2-amine moiety and the backbone of two consecutive amino acids in the hinge region of the ATP binding pocket of GSK-3β, Tyr134 and Val135. Both ring nitrogens presumably act as hydrogen bond acceptors towards the NH bonds of both amino acids while the exocyclic NH is accepted by the carbonyl oxygen of Val 135. The fact that the hydrogen bond pattern observed in here matches the one predicted for the enzyme-inhibitor complex emphasizes the 2-amino-1,3,4-oxadiazole system as a structural element privileged for interaction with the ATP binding pockets of kinases and other proteins [<xref ref-type="bibr" rid="B22-crystals-02-01201">22</xref>].</p>
      <fig id="crystals-02-01201-f003" position="anchor">
        <label>Figure 3</label>
        <caption>
          <p>Crystal packing of <bold>2</bold>. Dashed lines are indicating hydrogen bond contacts. Lattice constants are shown in different colors: (<bold>a</bold>) red; (<bold>b</bold>) green; (<bold>c</bold>) blue.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="crystals-02-01201-g003.tif"/>
      </fig>
      <table-wrap id="crystals-02-01201-t003" position="anchor">
        <object-id pub-id-type="pii">crystals-02-01201-t003_Table 3</object-id>
        <label>Table 3</label>
        <caption>
          <p>Interatomic distances and geometries for hydrogen bonds in the crystal structure of <bold>2</bold>.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th align="center" valign="middle">D-H...A</th>
              <th align="center" valign="middle">d(D-H) (Å)</th>
              <th align="center" valign="middle">d(H...A) (Å)</th>
              <th align="center" valign="middle">d(D...A) (Å)</th>
              <th align="center" valign="middle">Ë (D-HA) (°)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="center" valign="middle">N(1)-H(1)...N(3) <sup>i</sup></td>
              <td align="center" valign="middle">0.87(1)</td>
              <td align="center" valign="middle">2.04(1)</td>
              <td align="center" valign="middle">2.90(1)</td>
              <td align="center" valign="middle">168(1)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">N(4)-H(4A)...O(1) <sup>ii</sup></td>
              <td align="center" valign="middle">0.88(1)</td>
              <td align="center" valign="middle">2.32(1)</td>
              <td align="center" valign="middle">3.17(1)</td>
              <td align="center" valign="middle">164(1)</td>
            </tr>
            <tr>
              <td align="center" valign="middle">N(4)-H(4B)...N(2) <sup>iii</sup></td>
              <td align="center" valign="middle">0.89(1)</td>
              <td align="center" valign="middle">2.55(1)</td>
              <td align="center" valign="middle">3.40(2)</td>
              <td align="center" valign="middle">161(1)</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
        <fn>
        <p>Symmetry codes for generation of equivalent atoms: <sup>i</sup>: −x + 1, y − 1/2, −z + 1; <sup>ii</sup>: − x+ 1, y + 1/2, −z; <sup>iii</sup>: −x + 1, y + 1/2, −z + 1.</p>
        </fn>
        </table-wrap-foot>
      </table-wrap>
      
      
      <p>Considering the packing of the molecules in the crystal, interactions between the phenyl rings of the carbobenzoxy and phenylalanine-derived moieties of adjacent molecules become obvious. These interactions can be interpreted as aromatic T-shaped or edge-to-face contacts as indicated by alternating centroid-centroid distances of 5.247 Å and 4.777 Å (<xref ref-type="fig" rid="crystals-02-01201-f004">Figure 4</xref>). The angle of inclination between the planes of the adjacent phenyl rings is 74.83°, corresponding to a deviation of 25.17° from the ideal perpendicular orientation [<xref ref-type="bibr" rid="B23-crystals-02-01201">23</xref>,<xref ref-type="bibr" rid="B24-crystals-02-01201">24</xref>]. This suggests that the intermolecular forces in the crystal are strongly determined by aromatic interactions originating from the two phenyl rings of the compound in addition to hydrogen bond contacts.</p>
      <fig id="crystals-02-01201-f004" position="anchor">
        <label>Figure 4</label>
        <caption>
          <p>Aromatic interactions in the crystal packing of <bold>2</bold> illustrated by centroid-centroid distances in Å.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="crystals-02-01201-g004.tif"/>
      </fig>
    </sec>
    <sec>
      <title>3. Experimental Section</title>
      <p>Melting points were determined on a Büchi 510 oil bath apparatus and are not corrected. Thin layer chromatography was performed on Merck aluminum sheets. Optical rotations were determined on a Perkin-Elmer 241 polarimeter. <sup>1</sup>H NMR spectra (500 MHz) and <sup>13</sup>C NMR spectra (125 MHz) were recorded on a Bruker Avance 500 spectrometer. Mass spectra were obtained on an A.E.I. MS-50 spectrometer (EI, 70 eV). </p>
      <sec>
        <title>3.1. Synthesis of Benzyl [(1<italic>S</italic>)-1-(5-amino-1,3,4-oxadiazol-2-yl)-2-phenylethyl]carbamate (<italic><bold>2</bold></italic>)</title>
        <p>To a solution of <italic>N</italic>-(benzyloxycarbonyl)-phenylalanine hydrazide (<bold>1</bold>; prepared as published in [<xref ref-type="bibr" rid="B3-crystals-02-01201">3</xref>]; 0.30 g, 0.96 mmol) in methanol (10 mL) and THF (5 mL), sodium acetate (0.22 g, 2.69 mmol) and cyanogen bromide (0.11 g, 1.10 mmol) were added as solids. Caution: cyanogen bromide is highly toxic and may cause death by inhalation. It should be handled in a well ventilated hood only with the utmost care. After stirring for 8 h at room temperature the solvent was removed <italic>in vacuo</italic> and the obtained residue was washed with water, dried in a desiccator over P<sub>4</sub>O<sub>10</sub> and recrystallized from petroleum ether/ethyl acetate to afford <bold>2</bold> (0.19 g, 58%) as colorless crystals. m.p. 142–144 °C; [α]<sub>D</sub><sup>20</sup> = −41.5° (c = 1.88, dioxane); <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ in ppm = 3.14 (dd, <sup>2</sup><italic>J</italic> = 12.6 Hz, <sup>3</sup><italic>J</italic> = 6.9 Hz, 1H, C10HH); 3.25 (dd, <sup>2</sup><italic>J</italic> = 13.9 Hz, <sup>3</sup><italic>J </italic>= 6.3 Hz, 1H, C10HH); 5.03 (d, <sup>2</sup><italic>J</italic> = 12.3 Hz, 1H, C2HH); 5.07 (d, <sup>2</sup><italic>J</italic> = 12.3 Hz, 1H, C2HH); 5.13-5.20 (m, 1H, C9H); 5.31 (br s, 2H, N4H<sub>2</sub>); 5.40 (d, <sup>3</sup><italic>J</italic> = 8.9 Hz, 1H, N1H); 7.09–7.13 (m, 2H, C16H/C12H); 7.18–7.34 (m, 8H, H<sub>arom</sub>); <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ in ppm = 39.15 (C10); 48.56 (C9); 67.17 (C2); 127.21 (C14); 128.05 (C4/C8); 128.22 (C6); 128.52, 128.68, 129.32 (C12/C16, C13/C15, C5/C7); 135.37, 136.02 (C11, C3); 155.54 (C1); 159.98 (C18); 163.10 (C17); MS (EI) <italic>m/z</italic> (%): 338 (10, M<sup>+</sup>); 247 (18, [M-C<sub>7</sub>H<sub>7</sub>]<sup>+</sup>); 230 (15, [M-C<sub>7</sub>H<sub>7</sub>-NH<sub>3</sub>]<sup>+</sup>); 203 (10, [M-BnOCO]<sup>+</sup>); 91 (100, C<sub>7</sub>H<sub>7</sub><sup>+</sup>).</p>
      </sec>
      <sec>
        <title>3.2. Crystal Structure Determination</title>
        <p>The X-ray crystal structure of compound <bold>2</bold> was determined with a Nonius KappaCCD diffractometer at a temperature of 123 K and a wavelength of 0.71073 Å (Mo-<italic>K</italic><sub>α</sub> radiation). The structure was solved by direct methods using the program SHELXS-97, refinement was done with SHELXL-97 (both programs are part of SHELX-97 [<xref ref-type="bibr" rid="B25-crystals-02-01201">25</xref>]). Non-hydrogen atoms were refined anisotropically and hydrogens with a riding model. Exceptionally, hydrogen atoms bound to nitrogen were refined freely. The absolute configuration has not been established by anomalous dispersion effects in diffraction measurement on the crystal. The enantiomer has been assigned by reference to an unchanging chiral centre in the synthetic procedure. Structures were visualized and evaluated using Mercury 3.0, The Cambridge Crystallographic Data Centre [<xref ref-type="bibr" rid="B26-crystals-02-01201">26</xref>]. Errors of presented bond lengths and angles are given in brackets and refer to the last decimal place.</p>
        <p>Crystallographic data (excluding structure factors) for the structure reported in this work have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication no. CCDC 884101 (<bold>2</bold>). Copies of the data can be obtained free of charge on application to The Director, CCDC, 12 Union Road, Cambridge DB2 1EZ, UK.</p>
      </sec>
    </sec>
    <sec sec-type="conclusions">
      <title>4. Conclusions</title>
      <p>The title compound <bold>2</bold> was prepared and its molecular structure was deduced from its X-ray diffraction pattern. This unequivocally confirms the non-existence of <italic>N</italic>’-cyanohydrazides bearing hydrogen atoms at both nitrogens due to spontaneous cyclization to 2-amino-1,3,4-oxadiazoles. To the best of our knowledge, a crystal structure of an amino acid-derived 2-amino-1,3,4-oxadiazole has not been reported before.</p>
      <p>An extensive network of hydrogen bonds as well as edge-to-face interactions could be identified in the crystal packing. The observed hydrogen bond pattern involving the heterocycle as well the exocyclic amino group supports the importance of such moieties for the design of biologically active molecules able to interact with the ATP-binding pockets of some proteins. </p>
    </sec>
   
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p>We are grateful to Gloria Ruiz Gómez for support regarding the graphical presentation of the structures.</p>
    </ack>
    <notes>
      <title>Conflict of Interest</title>
      <p>The authors declare no conflict of interest.</p>
    </notes>
    <ref-list>
      <title>References</title>
      <ref id="B1-crystals-02-01201">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Proulx</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Sabatino</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hopewell</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Spiegel</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Garcia Ramos</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Lubell</surname>
              <given-names>W.D.</given-names>
            </name>
          </person-group>
          <article-title>Azapeptides and their therapeutic potential</article-title>
          <source>Future Med. Chem.</source>
          <year>2011</year>
          <volume>3</volume>
          <fpage>1139</fpage>
          <lpage>1164</lpage>
          <pub-id pub-id-type="doi">10.4155/fmc.11.74</pub-id>
        </citation>
      </ref>
      <ref id="B2-crystals-02-01201">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frizler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Stirnberg</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sisay</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Gütschow</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Development of nitrile-based peptidic inhibitors of cysteine cathepsins</article-title>
          <source>Curr. Top. Med. Chem.</source>
          <year>2010</year>
          <volume>10</volume>
          <fpage>294</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="doi">10.2174/156802610790725452</pub-id>
        </citation>
      </ref>
      <ref id="B3-crystals-02-01201">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Löser</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Frizler</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Schilling</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Gütschow</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Azadipeptide nitriles: Highly potent and proteolytically stable inhibitors of papain-like cysteine proteases</article-title>
          <source>Angew. Chem. Int. Ed.</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>4331</fpage>
          <lpage>4334</lpage>
        <pub-id pub-id-type="doi">10.1002/anie.200705858</pub-id></citation>
      </ref>
      <ref id="B4-crystals-02-01201">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loh</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hua</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>S.Q.</given-names>
            </name>
          </person-group>
          <article-title>“Click” synthesis of small molecule-peptide conjugates for organelle-specific delivery and inhibition of lysosomal cysteine proteases</article-title>
          <source>Chem. Commun.</source>
          <year>2010</year>
          <volume>46</volume>
          <fpage>8407</fpage>
          <lpage>8409</lpage>
        <pub-id pub-id-type="doi">10.1039/c0cc03738a</pub-id></citation>
      </ref>
      <ref id="B5-crystals-02-01201">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hetzheim</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Möckel</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Recent advances in 1,3,4-oxadiazole chemistry</article-title>
          <source>Adv. Heterocycl. Chem.</source>
          <year>1967</year>
          <volume>7</volume>
          <fpage>183</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="doi">10.1016/S0065-2725(08)60591-7</pub-id>
        </citation>
      </ref>
      <ref id="B6-crystals-02-01201">
        <label>6.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Hetzheim</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>1,3,4-Oxadiazole</article-title>
          <source>Houben-Weyl Methoden der Organischen Chemie (In German)</source>
          <person-group person-group-type="editor">
            <name>
              <surname>Schaumann</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <publisher-name>Georg Thieme Verlag</publisher-name>
          <publisher-loc>Stuttgart, Germany</publisher-loc>
          <year>1994</year>
          <fpage>526</fpage>
          <lpage>647</lpage>
        </citation>
      </ref>
      <ref id="B7-crystals-02-01201">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gehlen</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Über N<sup>β</sup>-Cyan-säurehydrazide und ihre Umwandlung in 1,2,4-Triazolone-3 (In German)</article-title>
          <source>Liebigs Ann. Chem.</source>
          <year>1949</year>
          <volume>563</volume>
          <fpage>185</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="doi">10.1002/jlac.19495630203</pub-id>
        </citation>
      </ref>
      <ref id="B8-crystals-02-01201">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Zhan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>1,3,4-Oxadiazole: A privileged structure in antiviral agents</article-title>
          <source>Mini-Rev. Med. Chem.</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>1130</fpage>
          <lpage>1142</lpage>
          <pub-id pub-id-type="doi">10.2174/138955711797655407</pub-id>
        </citation>
      </ref>
      <ref id="B9-crystals-02-01201">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boström</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Hogner</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Llinas</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Wellner</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Plowright</surname>
              <given-names>A.T.</given-names>
            </name>
          </person-group>
          <article-title>Oxadiazoles in medicinal chemistry</article-title>
          <source>J. Med. Chem.</source>
          <year>2012</year>
          <volume>55</volume>
          <fpage>1817</fpage>
          <lpage>1830</lpage>
          <pub-id pub-id-type="doi">10.1021/jm2013248</pub-id>
        </citation>
      </ref>
      <ref id="B10-crystals-02-01201">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oyston</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Batsanov</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Perepichka</surname>
              <given-names>I.F.</given-names>
            </name>
            <name>
              <surname>Bryce</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>J.H.</given-names>
            </name>
            <name>
              <surname>Pearson</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Petty</surname>
              <given-names>M.C.</given-names>
            </name>
          </person-group>
          <article-title>New 2,5-diaryl-1,3,4-oxadiazole–fluorene hybrids as electron transporting materials for blended-layer organic light emitting diodes</article-title>
          <source>J. Mater. Chem.</source>
          <year>2005</year>
          <volume>15</volume>
          <fpage>194</fpage>
          <lpage>203</lpage>
        <pub-id pub-id-type="doi">10.1039/b413066a</pub-id></citation>
      </ref>
      <ref id="B11-crystals-02-01201">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagendra</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lamani</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Narendra</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Sureshbabu</surname>
              <given-names>V.V.</given-names>
            </name>
          </person-group>
          <article-title>A convenient synthesis of1,3,4-thiadiazole and 1,3,4-oxadiazole based peptidomimetics employing diacylhydrazines derived from amino acids</article-title>
          <source>Tetrahedron Lett.</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>6338</fpage>
          <lpage>6341</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tetlet.2010.09.122</pub-id></citation>
      </ref>
      <ref id="B12-crystals-02-01201">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ko</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Burgess</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Minimalist and universal peptidomimetics</article-title>
          <source>Chem. Soc. Rev.</source>
          <year>2011</year>
          <volume>40</volume>
          <fpage>4411</fpage>
          <lpage>4421</lpage>
          <pub-id pub-id-type="doi">10.1039/c0cs00218f</pub-id>
        </citation>
      </ref>
      <ref id="B13-crystals-02-01201">
        <label>13.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Ritzeler</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Stilz</surname>
              <given-names>H.U.</given-names>
            </name>
            <name>
              <surname>Neises</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bock</surname>
              <given-names>W.J.</given-names>
              <suffix>Jr.</suffix>
            </name>
            <name>
              <surname>Walser</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Flynn</surname>
              <given-names>G.A.</given-names>
            </name>
          </person-group>
          <article-title>Preparation of Benzimidazolecarboxylic Acid Amino Acid Amides as IκB Kinase Inhibitors</article-title>
          <source>Eur. Pat. Appl.</source>
          <patent>5340, 2000</patent>
        </citation>
      </ref>
      <ref id="B14-crystals-02-01201">
        <label>14.</label>
        <citation citation-type="patent">
          <person-group person-group-type="author">
            <name>
              <surname>Buchler</surname>
              <given-names>I.P.</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Hedge</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Hockerman</surname>
              <given-names>S.L.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>D.E.</given-names>
            </name>
            <name>
              <surname>Kortum</surname>
              <given-names>S.W.</given-names>
            </name>
            <name>
              <surname>Rico</surname>
              <given-names>J.G.</given-names>
            </name>
            <name>
              <surname>TenBrink</surname>
              <given-names>R.E.</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>K.K.</given-names>
            </name>
          </person-group>
          <article-title>Indazole Derivatives as CB1 Receptor Modulators and Their Preparation and Use in the Treatment of CB<sub>1</sub>-Mediated Diseases</article-title>
          <source>Eur. Pat. Appl.</source>
          <patent>106982, 2009</patent>
        </citation>
      </ref>
      <ref id="B15-crystals-02-01201">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lamani</surname>
              <given-names>R.S.</given-names>
            </name>
            <name>
              <surname>Nagendra</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Sureshbabu</surname>
              <given-names>V.V.</given-names>
            </name>
          </person-group>
          <article-title>A facile synthesis of N-Z/Boc-protected 1,3,4-oxadiazole-based peptidomimetics employing peptidyl thiosemicarbazides</article-title>
          <source>Tetrahedron Lett.</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>4705</fpage>
          <lpage>4709</lpage>
        <pub-id pub-id-type="doi">10.1016/j.tetlet.2010.07.004</pub-id></citation>
      </ref>
      <ref id="B16-crystals-02-01201">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flack</surname>
              <given-names>H.D.</given-names>
            </name>
          </person-group>
          <article-title>On enantiomorph-polarity estimation</article-title>
          <source>Acta Cryst.</source>
          <year>1983</year>
          <volume>A39</volume>
          <fpage>876</fpage>
          <lpage>881</lpage>
        </citation>
      </ref>
      <ref id="B17-crystals-02-01201">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hooft</surname>
              <given-names>R.W.W.</given-names>
            </name>
            <name>
              <surname>Straver</surname>
              <given-names>L.H.</given-names>
            </name>
            <name>
              <surname>Spek</surname>
              <given-names>A.L.</given-names>
            </name>
          </person-group>
          <article-title>Determination of absolute structure using Bayesian statistics on Bijvoet differences</article-title>
          <source>J. Appl. Cryst.</source>
          <year>2008</year>
          <volume>41</volume>
          <fpage>96</fpage>
          <lpage>103</lpage>
          <pub-id pub-id-type="doi">10.1107/S0021889807059870</pub-id>
        </citation>
      </ref>
      <ref id="B18-crystals-02-01201">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flack</surname>
              <given-names>H.D.</given-names>
            </name>
          </person-group>
          <article-title>Chiral and achiral crystal structures</article-title>
          <source>Helv. Chim. Acta</source>
          <year>2003</year>
          <volume>86</volume>
          <fpage>905</fpage>
          <lpage>921</lpage>
          <pub-id pub-id-type="doi">10.1002/hlca.200390109</pub-id>
        </citation>
      </ref>
      <ref id="B19-crystals-02-01201">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brittain</surname>
              <given-names>H.G.</given-names>
            </name>
          </person-group>
          <article-title>Crystallographic consequences of molecular dissymmetry</article-title>
          <source>Pharm. Res.</source>
          <year>1990</year>
          <volume>7</volume>
          <fpage>683</fpage>
          <lpage>690</lpage>
          <pub-id pub-id-type="doi">10.1023/A:1015851118787</pub-id>
        </citation>
      </ref>
      <ref id="B20-crystals-02-01201">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allen</surname>
              <given-names>F.H.</given-names>
            </name>
            <name>
              <surname>Kennard</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Watson</surname>
              <given-names>D.G.</given-names>
            </name>
            <name>
              <surname>Brammer</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Orpen</surname>
              <given-names>A.G.</given-names>
            </name>
            <name>
              <surname>Taylor</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds</article-title>
          <source>J. Chem. Soc. Perkin Trans.</source>
          <year>1997</year>
          <volume>12</volume>
          <fpage>S1</fpage>
          <lpage>S19</lpage>
        </citation>
      </ref>
      <ref id="B21-crystals-02-01201">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khanfar</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Kaddoumi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>El Sayed</surname>
              <given-names>K.A.</given-names>
            </name>
          </person-group>
          <article-title>Discovery of novel GSK-3β inhibitors with potent <italic>in vitro</italic> and <italic>in vivo</italic> activities and excellent brain permeability using combined ligand- and structure-based virtual Screening</article-title>
          <source>J. Med. Chem.</source>
          <year>2010</year>
          <volume>53</volume>
          <fpage>8534</fpage>
          <lpage>8545</lpage>
          <pub-id pub-id-type="doi">10.1021/jm100941j</pub-id>
        </citation>
      </ref>
      <ref id="B22-crystals-02-01201">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mao</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>X.</given-names>
            </name>
          </person-group>
          <article-title>Molecular determinants for ATP-binding in proteins: A data mining and quantum chemical analysis</article-title>
          <source>J. Mol. Biol.</source>
          <year>2004</year>
          <volume>336</volume>
          <fpage>787</fpage>
          <lpage>807</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmb.2003.12.056</pub-id>
        </citation>
      </ref>
      <ref id="B23-crystals-02-01201">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klebe</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Diederich</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>A comparison of the crystal packing in benzene with the geometry seen in crystalline cyclophane-benzene complexes: Guidelines for rational receptor design</article-title>
          <source>Philos. Trans. R. Soc. Lond. A</source>
          <year>1993</year>
          <volume>345</volume>
          <fpage>37</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="doi">10.1098/rsta.1993.0115</pub-id>
        </citation>
      </ref>
      <ref id="B24-crystals-02-01201">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meyer</surname>
              <given-names>E.A.</given-names>
            </name>
            <name>
              <surname>Castellano</surname>
              <given-names>R.K.</given-names>
            </name>
            <name>
              <surname>Diederich</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Interactions with aromatic rings in chemical and biological recognition</article-title>
          <source>Angew. Chem. Int. Ed.</source>
          <year>2003</year>
          <volume>42</volume>
          <fpage>1210</fpage>
          <lpage>1250</lpage>
          <pub-id pub-id-type="doi">10.1002/anie.200390319</pub-id>
        </citation>
      </ref>
      <ref id="B25-crystals-02-01201">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheldrick</surname>
              <given-names>G.M.</given-names>
            </name>
          </person-group>
          <article-title>A short history of SHELX</article-title>
          <source>Acta Cryst.</source>
          <year>2008</year>
          <volume>A64</volume>
          <fpage>112</fpage>
          <lpage>122</lpage>
        </citation>
      </ref>
      <ref id="B26-crystals-02-01201">
        <label>26.</label>
        <citation citation-type="web">
          <article-title>Mercury</article-title>
          <access-date>(accessed on 24 May 2012)</access-date>
          <comment>Available online:<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.ccdc.cam.ac.uk/free_services/mercury/downloads/Mercury_3.0/" ext-link-type="uri">http://www.ccdc.cam.ac.uk/free_services/mercury/downloads/Mercury_3.0/</ext-link></comment>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
